Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence

Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Changes in the biological marker status between primary and recurrent tumors are observed in breast cancer. However, their clinical significance is still uncertain, especially for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery. Patients and methods: A total of 117 patients with IBTR without distant metastases were enrolled in this study. All patients were examined for estrogen receptor (ER), HER2, and Ki-67 in both the primary tumors and paired IBTR. We evaluated the impact of changes in these biomarkers between primary tumors and IBTR on the prognosis after IBTR. Results: There were no associations of changes in the ER, HER2 status with distant disease-free survival (DDFS) after surgical resection of IBTR, whereas the change in the Ki-67 status between the primary tumors and IBTR was significantly correlated with DDFS (unadjusted: p = 0.0094; adjusted: p = 0.013). Patients in the "increased or remained high" Ki-67 group had a significantly shorter DDFS than those in the "decreased or remained low" Ki-67 group (5-year DDFS: 55.5 vs. 79.3%, respectively, p = 0.0084 by log-rank test). Conclusion: An increased or persistently high Ki-67 status in the IBTR was significantly correlated with a poorer prognosis after IBTR.

Original languageEnglish
Pages (from-to)548-552
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume41
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Estrogen Receptors
Breast Neoplasms
Recurrence
Disease-Free Survival
Neoplasms
Biomarkers
Segmental Mastectomy
Neoplasm Metastasis

Keywords

  • Breast cancer
  • Ipsilateral breast tumor recurrence
  • Ki-67

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Medicine(all)

Cite this

Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. / Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

In: European Journal of Surgical Oncology, Vol. 41, No. 4, 2015, p. 548-552.

Research output: Contribution to journalArticle

Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. / Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence. In: European Journal of Surgical Oncology. 2015 ; Vol. 41, No. 4. pp. 548-552.
@article{8ffeaf1f767e4590ad6c554859da99d5,
title = "Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence",
abstract = "Introduction: Changes in the biological marker status between primary and recurrent tumors are observed in breast cancer. However, their clinical significance is still uncertain, especially for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery. Patients and methods: A total of 117 patients with IBTR without distant metastases were enrolled in this study. All patients were examined for estrogen receptor (ER), HER2, and Ki-67 in both the primary tumors and paired IBTR. We evaluated the impact of changes in these biomarkers between primary tumors and IBTR on the prognosis after IBTR. Results: There were no associations of changes in the ER, HER2 status with distant disease-free survival (DDFS) after surgical resection of IBTR, whereas the change in the Ki-67 status between the primary tumors and IBTR was significantly correlated with DDFS (unadjusted: p = 0.0094; adjusted: p = 0.013). Patients in the {"}increased or remained high{"} Ki-67 group had a significantly shorter DDFS than those in the {"}decreased or remained low{"} Ki-67 group (5-year DDFS: 55.5 vs. 79.3{\%}, respectively, p = 0.0084 by log-rank test). Conclusion: An increased or persistently high Ki-67 status in the IBTR was significantly correlated with a poorer prognosis after IBTR.",
keywords = "Breast cancer, Ipsilateral breast tumor recurrence, Ki-67",
author = "{Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society} and Y. Okumura and R. Nishimura and K. Nakatsukasa and A. Yoshida and N. Masuda and M. Tanabe and Tadahiko Shien and S. Tanaka and N. Arima and Y. Komoike and T. Taguchi and T. Iwase and H. Inaji and M. Ishitobi",
year = "2015",
doi = "10.1016/j.ejso.2015.01.030",
language = "English",
volume = "41",
pages = "548--552",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence

AU - Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

AU - Okumura, Y.

AU - Nishimura, R.

AU - Nakatsukasa, K.

AU - Yoshida, A.

AU - Masuda, N.

AU - Tanabe, M.

AU - Shien, Tadahiko

AU - Tanaka, S.

AU - Arima, N.

AU - Komoike, Y.

AU - Taguchi, T.

AU - Iwase, T.

AU - Inaji, H.

AU - Ishitobi, M.

PY - 2015

Y1 - 2015

N2 - Introduction: Changes in the biological marker status between primary and recurrent tumors are observed in breast cancer. However, their clinical significance is still uncertain, especially for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery. Patients and methods: A total of 117 patients with IBTR without distant metastases were enrolled in this study. All patients were examined for estrogen receptor (ER), HER2, and Ki-67 in both the primary tumors and paired IBTR. We evaluated the impact of changes in these biomarkers between primary tumors and IBTR on the prognosis after IBTR. Results: There were no associations of changes in the ER, HER2 status with distant disease-free survival (DDFS) after surgical resection of IBTR, whereas the change in the Ki-67 status between the primary tumors and IBTR was significantly correlated with DDFS (unadjusted: p = 0.0094; adjusted: p = 0.013). Patients in the "increased or remained high" Ki-67 group had a significantly shorter DDFS than those in the "decreased or remained low" Ki-67 group (5-year DDFS: 55.5 vs. 79.3%, respectively, p = 0.0084 by log-rank test). Conclusion: An increased or persistently high Ki-67 status in the IBTR was significantly correlated with a poorer prognosis after IBTR.

AB - Introduction: Changes in the biological marker status between primary and recurrent tumors are observed in breast cancer. However, their clinical significance is still uncertain, especially for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery. Patients and methods: A total of 117 patients with IBTR without distant metastases were enrolled in this study. All patients were examined for estrogen receptor (ER), HER2, and Ki-67 in both the primary tumors and paired IBTR. We evaluated the impact of changes in these biomarkers between primary tumors and IBTR on the prognosis after IBTR. Results: There were no associations of changes in the ER, HER2 status with distant disease-free survival (DDFS) after surgical resection of IBTR, whereas the change in the Ki-67 status between the primary tumors and IBTR was significantly correlated with DDFS (unadjusted: p = 0.0094; adjusted: p = 0.013). Patients in the "increased or remained high" Ki-67 group had a significantly shorter DDFS than those in the "decreased or remained low" Ki-67 group (5-year DDFS: 55.5 vs. 79.3%, respectively, p = 0.0084 by log-rank test). Conclusion: An increased or persistently high Ki-67 status in the IBTR was significantly correlated with a poorer prognosis after IBTR.

KW - Breast cancer

KW - Ipsilateral breast tumor recurrence

KW - Ki-67

UR - http://www.scopus.com/inward/record.url?scp=84929942116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929942116&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2015.01.030

DO - 10.1016/j.ejso.2015.01.030

M3 - Article

C2 - 25682910

AN - SCOPUS:84929942116

VL - 41

SP - 548

EP - 552

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 4

ER -